Urogen Pharma Ltd banner

Urogen Pharma Ltd
NASDAQ:URGN

Watchlist Manager
Urogen Pharma Ltd Logo
Urogen Pharma Ltd
NASDAQ:URGN
Watchlist
Price: 17.62 USD -5.22% Market Closed
Market Cap: $824.8m

Wall Street
Price Targets

URGN Price Targets Summary
Urogen Pharma Ltd

Wall Street analysts forecast URGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for URGN is 35.96 USD with a low forecast of 16.16 USD and a high forecast of 57.75 USD.

Lowest
Price Target
16.16 USD
8% Downside
Average
Price Target
35.96 USD
104% Upside
Highest
Price Target
57.75 USD
228% Upside
Urogen Pharma Ltd Competitors:
Price Targets

Revenue
Forecast

N/A
Past Growth
72% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
N/A
Past Growth
72% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

The compound annual growth rate of Urogen Pharma Ltd's revenue for the next 3 years is 72%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-52%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-52%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is URGN's stock price target?
Price Target
35.96 USD

According to Wall Street analysts, the average 1-year price target for URGN is 35.96 USD with a low forecast of 16.16 USD and a high forecast of 57.75 USD.

What is Urogen Pharma Ltd's Revenue forecast?
Projected CAGR
72%

The compound annual growth rate of Urogen Pharma Ltd's revenue for the next 3 years is 72%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett